Details
Category: Volume 06 Issue 10 October 2018
Hits: 984

Title: A Prevalence Study on Serum Lipoprotein (a) and Serum LDL level in Stroke

Authors: Rakesh Sebastin Xavier, Chidambaram Natesan, Periasamy Subbarayan

 DOI:  https://dx.doi.org/10.18535/jmscr/v6i10.144

Abstract

Background: Stroke is the second leading reason for mortality and morbidity in the world. Many studies indicate an elevated Lipoprotein (a) {Lp(a)} level in individuals with acute cerebral ischemia. The role of Lp(a) in acute stroke is unclear. Increased LDL level is found in various atherothrombotic manifestations including stroke. In this study we discuss the mechanisms, by which Lp(a) may cause stroke. We also studied the association between serum LDL level and Lp(a) in acute patients having stroke. Medical interventions to reduce the Lp(a) level are discussed.

Method: We analyzed serum LDL level and Lp(a) level in 100 cases of  stroke  admitted in the medical wards of Rajah Muthaiah Medical College during the period of September 2016 to  October 2018. Elevated Lp(a) level is defined as Serum Lp(a) >30 mg/dl.  We also the studied the relation between serum Lp(a) and serum LDL level.

Result: Serum Lp(a) was increased in 42 patients (42%) of acute cerebral ischemia. LDL level in the serum was increased in 19% of the patients with the mean LDL level of 109.12 mg/dl.  The study showed no positive correlation between serum LDL level and Lp(a) level (P value=0.74).

Conclusions: We observed from the study that Lp(a) level were elevated in 42% (  ) of the patients with acute ischemic stroke.  But no relation exists between serum Lp(a) and LDL levels.

Keywords: Acute Ischemic Stroke, Lipoprotein (a).

References

  1. American Heart Association, Heart and stroke facts: 1994 Statistical supplement. Dallas: American Heart Association, 1993.
  2. Warlow C. Burden of stroke. In: Donaghy M, editor. Brain’s disease of the nervous system, 11th ed. New York: Oxford University Press; 2001:777.
  3. West of Scotland Coronary Prevention Study Group. West of Scotland coronary prevention study: Identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet. 1996; 348:1339-2.
  4. The Pravastatin multinational study group for cardiac risk patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/l plus two additional atherosclerotic risk factors. Am J Cardiol. 1993;72:1031-7.
  5. Papadakis JA, Mikhailidis DP, Winder AF. Lipids and stroke. Neglects of a useful preventive measure?. Cardiovasc res 1998: 40: 265-71.
  6. Dahlen G. Lp (a) lipoprotein in cardiovascular disease. Atherosclerosis. 1994;108:111-26.
  7. Konemari G. Lipoprotein (a) and other risk factors for cerebral infarction. Hiroshima J Med Sci. 1995;44:65-77
  8. Dahlen G. Lp (a) lipoprotein in cardiovascular disease. Atherosclerosis. 1994;108:111-26.
  9. Cheng SW ting AC, Wong J. Lipoprotien (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. Eur J Vasc Endovasc surgery 1997:14:17:-23.
  10. Konemari G. Lipoprotein (a) and other risk factors for cerebral infarction. Hiroshima J Med Sci. 1995;44:65-77
  11. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein (a). Nature. 1989; 339 (6222): 301-3.
  12. Huby T, Chapman J Thillet J. Pathophysiological implication of the structural domains of lipoprotein (a). Arthrosclerosis 1997;133:1-6.
  13. IKeok, Takahashik, Gojobori T. Different evolutionary histories of kringle and postease domains in serine proteases: A typical example of domain evolution. J Mol Evol 1995; 40:331-6.
  14. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human lipoprotein (a) is homologous to plasminogen. Nature 1987;330:132-7
  15. Byme C, Lawn R. Studies on the structure and function of the apolipoprtien (a) gene. Clin Genet 1994;46:34-31.
  16. Van der Hoek YY, Wittekoek ME, Beisegen U et al. The Apolipoprotein (a) kringle IV repeats are present in variably sized isoforms, Hum mol Genet 1993;2:361-6.
  17. Marcinova SM, Hobbis HH, Alberts JJ. Relation between number of Apoprotein (a) kningle 4 repeats and mobility of isoforms in agarose gel. Basis of a standardized isoform nomenclature. Clin chem 1996; 42: 436-9.
  18. Boerwinkle E, Leffert C, Lin J, et al, Apolipoprotein (a) gene accounts of greater than 90% of the variation in plasma lipoprotein concentrations. J clin Invest 1992:90; 52-60.
  19. Nagayama M, Shinohara Y, Nagayama T. Lipoprotein (a) and ischemic cerebrovascular disease in young adults. Stroke. 1994; 25:74-8.
  20. Nielsel LB, Arthrogencity of lipoprotein (a) and oxidized low density lipoprotein (a): Insight from in vivo studies of arterial wall influx, degradation and efflux. Arthrosclerosis, 1999 Vol, 143 pg (229-243).
  21. Tsimikan et al, New insights into the role of lipoprotein (a) associated pospholipase A2 in artherosclerosis and cardiovascular disease, Arterioscler Thromb Vasc Biol, 2007; Vol 27; 2094-99.
  22. Rouy D, Grailhe P, Nigon F, Chapman J, Angles – Cano E, Lipoprotien (a) impairs generation of plasmin by fibrin bound tisure type plasminogen activator. In vitro studies in plasma mileu. Arlerioscler thomb vasc biol 1991: vol 11 (Pg 629-33).
  23. Sotirious SN, Orlova VV, Al Fakhri, Ihanus F, Econompoulav N, Isermann B, Lipoprotien (a) in artherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J; 2006: Vol 20(Pg 559-61).
  24. Hervio L, Chapman MJ, Thillet J, Loyau S, Anglés-Cano E. Does Apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis. Blood.1993;82:392–397.
  25. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human Apolipoprotein(a) is homologous to plasminogen. Nature; 330:132-137.
  26. Brunner C, Lobentanz EM, Pethoschramm A, Ernst A, Kang C, Dieplinger H, Muller HJ, Utermann G. The number of identical kringle repeats in Apolipoprotein (a) affects its processing and secretion by Hep G2 cells. J Biol Chem.1996 Dec 13:271(50); 32403-10.
  27. Smolder B, Lemmens R, Thijs V. Lipoprotien (a) and stroke; a meta analysis of observations studies. Stroke 2007; 38(6), 1956-66.
  28. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. Journal of the American Medical Association. 1996; 276(7):544-548.
  29. Nagayama M, Shinohara Y, Nagayama T. Lipoprotein (a) and ischemic cerebrovascular disease in young adults. Stroke. 1994;25:74-8.
  30. Vavernova H, Novotny D, Ficker L, Vlachova I, Chudackova T. Lipoprotein (a); a gentle risk factor for early ischemic cerebrovascular stroke. Vnitr lek 1993;39:979-87.
  31. Van Kooten F, Van Krimpen J, Dippel DW, Hoogerbrugge N, Koudstaal PJ. Lipoprotein(a) in patients with acute ischemic stroke. Stroke 1996 Jul; 27:1231–5.
  32. Peng DQ, Zhao SP, Wang JL.Lipoprotein (a) and Apolipoprotein E4 as independent risk factors for ischemic stroke. J Cardiovasc Risk:  1999 Feb; 6(1):1-6.
  33. Watts GF, Mazurkiewicz JC, Tonge et al. Lipoprotein(a) as a determinant of the severity of angiographically defined atherosclerosis. Qf med: 1995 May; 88(5): 321-326.
  34. Hornstra G, Van Houwelingen AC, Kester ADM, Sundram K. A palm oil-enriched diet lowers serum lipoprotein (a) in normo- cholesterolemic volunteers. Atherosclerosis: 1991 Sep; 90(1): 91-93.
  35. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med: 1989 Oct; 226(4):271–276.
  36. The Pravastatin multinational study group for cardiac risk patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/l plus two additional atherosclerotic risk factors. Am J Cardiol. 1993; 72:1031-7.
  37. Maggi FM, Poglinoica MR, De Michele L, et al, Beza fibrate lowers elevated plasma levels of fibrinogen and lipoprotein (a) in patients with type IIa and IIb dyslipoprotienaemia: Nutr metab cardiovasc dis 1994; 4: 215-20.
  38. Kostner GM, Krempler F, Lipoprotien (a). Curr opin Lipidol: 1992;3:279-84.
  39. Scanum AM, Artherothrombogenicity of lipoprotein(a): the debate. AM J Cardiol 1996; 82:260-330.

Corresponding Author

Chidambaram Natesan

Professor, Department of General Medicine, Rajah Muthiah Medical College Hospital

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.